Fludarabine, cyclophosphamide, and dexamethasone (FluCyD) combination is effective in pretreated low-grade non-Hodgkin's lymphoma

M. Lazzarino, E. Orlandi, M. Montillo, A. Tedeschi, G. Pagnucco, C. Astori, A. Corso, E. Brusamolino, L. Simoncini, E. Morra, C. Bernasconi

Research output: Contribution to journalArticle


Purpose: Fludarabine phosphate is effective as a single agent in low- grade non-Hodgkin's lymphoma (NHL). Combined with other antineoplastic agents it enhances the antitumor effect. Our aim was to define the therapeutic efficacy and toxicity of a combination of fludarabine, cyclophosphamide and dexamethasone (FluCyD) in patients with advanced low-grade lymphoma. Patients and methods: Twenty-five adults with pretreated advanced-stage low-grade NHL were treated with three-day courses of fludarabine 25 mg/m2/day, cyclophosphamide 350 mg/m2/day, and dexamethasone 20 mg/day, every four weeks for a maximum of six courses. Results: Of the 25 patients, 18 (72%) responded, 8 (32%) achieving CR and 10 (40%) PR. Seven were failures. The median follow-up was 21 months (5-26). Eight CR patients remain in CR after 5-21 months. Of 10 PR patients, 3 are in continuous PR without further treatment after 12, 17 and 18 months. Myelosuppression was the most prevalent toxic effect. Although severe granulocytopenia (granulocyte count nadir

Original languageEnglish
Pages (from-to)59-64
Number of pages6
JournalAnnals of Oncology
Issue number1
Publication statusPublished - 1999



  • Fludarabine
  • Non-Hodgkin's lymphoma

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this